Literature DB >> 30117766

Long-term outcomes among octogenarians with aneurysmal subarachnoid hemorrhage.

Hormuzdiyar Dasenbrock1,2, William B Gormley1,2, Yoojin Lee3, Vincent Mor3, Susan L Mitchell2,4, Corey R Fehnel2,4,5.   

Abstract

OBJECTIVE: Data evaluating the long-term outcomes, particularly with regard to treatment modality, of aneurysmal subarachnoid hemorrhage (SAH) in octogenarians are limited. The primary objectives were to evaluate the disposition (living at home vs institutional settings) and analyze the predictors of long-term survival and return to home for octogenarians after SAH.
METHODS: Data pertaining to patients age 80 and older who underwent microsurgical clipping or endovascular coiling for SAH were extracted from 100% nationwide Medicare inpatient claims and linked with the Minimum Data Set (2008-2011). Patient disposition was tracked for 2 years after index SAH admission. Multivariable logistic regression stratified by aneurysm treatment modality, and adjusted for patient factors including SAH severity, evaluated predictors of return to home at 60 and 365 days after SAH. Survival 365 days after SAH was analyzed with a multivariable Cox proportional hazards model.
RESULTS: A total of 1298 cases were included in the analysis. One year following SAH, 56% of the patients had died or were in hospice care, 8% were in an institutional post-acute care setting, and 36% had returned home. Open microsurgical clipping (adjusted hazard ratio [aHR] 0.67, 95% confidence interval [CI] 0.54-0.81), male sex (aHR 0.70, 95% CI 0.57-0.87), tracheostomy (aHR 0.63, 95% CI 0.47-0.85), gastrostomy (aHR 0.60, 95% CI 0.48-0.76), and worse SAH severity (aHR 0.94, 95% CI 0.92-0.97) were associated with reduced likelihood of patients ever returning home. Older age (aHR 1.09, 95% CI 1.05-1.13), tracheostomy (aHR 2.06, 95% CI 1.46-2.91), gastrostomy (aHR 1.55, 95% CI 1.14-2.10), male sex (aHR 1.66, 95% CI 1.20-2.23), and worse SAH severity 1.51 (95% CI 1.04-2.18) were associated with reduced survival.
CONCLUSIONS: In this national analysis, 56% of octogenarians with SAH died, and 36% returned home within 1 year of SAH. Coil embolization predicted returning to home, which may suggest a benefit to endovascular treatment in this patient population.

Entities:  

Keywords:  CI = confidence interval; CMS = Centers for Medicare & Medicaid Services; ICD-9-CM = International Classification of Diseases, 9th Revision, Clinical Modification; Medicare; Minimum Data Set; NIS = Nationwide Inpatient Sample; NIS-SSS = NIS SAH Severity Score; SAH = subarachnoid hemorrhage; aHR = adjusted hazard ratio; age; cerebral aneurysm; clipping; endovascular; long-term outcomes; octogenarians; subarachnoid hemorrhage; vascular disorders

Mesh:

Year:  2018        PMID: 30117766      PMCID: PMC6358513          DOI: 10.3171/2018.3.JNS173057

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  23 in total

1.  Subarachnoid haemorrhage in patients > or = 75 years: clinical course, treatment and outcome.

Authors:  D J Nieuwkamp; G J E Rinkel; R Silva; P Greebe; D A Schokking; J M Ferro
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04-25       Impact factor: 10.154

2.  Is aneurysm repair justified for the patients aged 80 or older after aneurysmal subarachnoid hemorrhage?

Authors:  Nobutake Sadamasa; Masaomi Koyanagi; Hitoshi Fukuda; Masaki Chin; Akira Handa; Sen Yamagata
Journal:  J Neurointerv Surg       Date:  2013-10-23       Impact factor: 5.836

3.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

4.  International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial.

Authors:  Andrew Molyneux; Richard Kerr; Irene Stratton; Peter Sandercock; Mike Clarke; Julia Shrimpton; Rury Holman
Journal:  Lancet       Date:  2002-10-26       Impact factor: 79.321

5.  Endovascular treatment for aneurysmal subarachnoid hemorrhage in the ninth decade of life and beyond.

Authors:  Thomas J Wilson; Matthew C Davis; William R Stetler; David A Giles; Neeraj Chaudhary; Joseph J Gemmete; B Gregory Thompson; Aditya S Pandey
Journal:  J Neurointerv Surg       Date:  2013-03-27       Impact factor: 5.836

6.  Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial.

Authors:  Jenifer H Voeks; George Howard; Gary S Roubin; Mahmoud B Malas; David J Cohen; W Charles Sternbergh; Herbert D Aronow; Mark K Eskandari; Alice J Sheffet; Brajesh K Lal; James F Meschia; Thomas G Brott
Journal:  Stroke       Date:  2011-10-06       Impact factor: 7.914

7.  Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care.

Authors:  Ying Xian; Emily C O'Brien; Gregg C Fonarow; DaiWai M Olson; Lee H Schwamm; Deidre Hannah; Brianna Lindholm; Lesley Maisch; Barbara L Lytle; Melissa A Greiner; Jingjing Wu; Eric D Peterson; Michael J Pencina; Adrian F Hernandez
Journal:  Am Heart J       Date:  2015-04-18       Impact factor: 4.749

8.  Aneurysm occlusion in elderly patients with aneurysmal subarachnoid haemorrhage: a cost-utility analysis.

Authors:  H Koffijberg; E Buskens; G J E Rinkel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-12-03       Impact factor: 10.154

Review 9.  Endovascular treatment of intracranial aneurysms in elderly patients: a systematic review and meta-analysis.

Authors:  Carmelo L Sturiale; Waleed Brinjikji; Mohammad H Murad; Giuseppe Lanzino
Journal:  Stroke       Date:  2013-05-16       Impact factor: 7.914

10.  Analysis of subarachnoid hemorrhage using the Nationwide Inpatient Sample: the NIS-SAH Severity Score and Outcome Measure.

Authors:  Chad W Washington; Colin P Derdeyn; Ralph G Dacey; Rajat Dhar; Gregory J Zipfel
Journal:  J Neurosurg       Date:  2014-06-20       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.